Event Overview

5 Reasons Why You Must Attend This Event!*

  1. Hear directly from decision making Payers, Hospitals & HTAs about current and emerging market access requirements
  2. Benchmark your product’s market access strategy whether it’s via HTA Evaluation, Tendering or Hospital Procurement
  3. Practice makes perfect - Use our Mock Payer Panels to sharpen your products’ value arguments in front of REAL PAYERS!
  4. Learn something new! With our fresh speaker lineup, you’ll hear current, relevant case studies based on actual market access experiences.
  5. Networking: Make real contact through our unrivalled networking with senior-level industry peers, payers & stakeholders and expert consultancies.

*Only for those looking to improve their MedTech products’ market access.

In the increasingly cost-contained world of medical device market access, Payers (including ministries of health, insurers private & public, hospitals and local governments) are seeking to justify investment in new medical technologies. Health Technology Assessment (HTA) agencies are now widely spreads across Europe assess new technologies and interventions not only on the grounds of clinical effectiveness, but also based on cost-effectiveness, cost-utility and cost-benefit, to ensure the payers’ limited funds are well invested. This HTA and value demonstration requirement has evolved the “commercialisation” landscape of medical devices across the world and this next barrier is one that all medical device companies seeking to gain reimbursement and approval from payers and tendering bodies, need to overcome.

The variety of commercial channels, customers and payers within the medical device space is as diverse as the different business models being used for the different product types (e.g. Imaging Vs Surgical products) and only increases the complexity and specificity of the “value message” which needs to well-delivered, in order to ensure an optimal outcome. This three-day event is the “must-attend” event for all senior directors at medical device companies who are looking to enhance market access for their products.

The first day will feature Europe’s leading payers, HTAs and market access KOLs discussing what they want to see from medical device manufacturers bringing new products to the market and will be a perfect opportunity to engage these key stakeholders. The second day of the event will contrast market access strategies for medical devices in key markets to enable market access and product managers to sequence and prioritise their product launch.

The different stakeholders involved in each market access process and the varying ways to engage them and demonstrate “value” for your technologies will be show from leading companies in the field for you to learn and benchmark from. Participants will leave this event armed with real-life, best practice examples of what is working and not working for your specific product type; what Payers and HTAs consider as essential and “nice to have” information to create “value”; and will have established relationships with the peers from the industry as well as influential decision-makers & KOLs in this sector. We look forward to meeting you in Berlin!

Speakers List

Payers, HTA Agencies & Policy Makers

Programme Officer European Commission eHealth, Well-being and Ageing (DG Connect)
European Commission

Legal & Policy Officer
European Commission

Director, Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA), Austria
Member, EUnetHTA

Associate Director of Medicines Optimisation, DGS & Swale CCGs
NHS

 

Senior Scientific Adviser
NICE - National Institute for Health and Care, UK

Scientific Coordinator, Agenas HTA Projects
Agenas (Agency for Regional Health Services), Italy

Director of Research and Education, Professor in Medical Biophysics
Region Jämtland Härjedalen, Östersund, Sweden

Head of Clinical Engineering Service
Humanitas Research Hospital, Italy

Member
RWE4Decisions - RIZIV/INAMI led HTA/Payer Initiative

Chief of development and communications
Center of Healthcare Quality Assessment and Control, The Ministry of Health of the Russian Federation

 

Associate Professor, Economic Evaluations in Health Care
Erasmus School of Health Policy and Management (ESHPM)
Institute for Medical Technology Assessment (iMTA)

Erasmus University Rotterdam, Netherlands

Senior Health Economist
Health Technology Wales, UK

Head of Department of Economic Evidence-based Health Care
Main Association of Austrian Social Insurance Institutions

Industry Experts

Senior Advisor
MedTech Europe

Jessica Imbert

Manager Market Access and Economic Policies
MedTech Europe, Belgium

Director Value-Based Healthcare
ValueConnected

Vice President, Innovation Program Manager
Philips Research

 

Foundation Medicine Access Innovation and PHC Lead, Pharma International, F. Hoffmann-La Roche
Chair of the “Funding Medical Technologies” group, MedTech Europe

Vice President Communications, Europe, Middle East & Africa
Medtronic

Senior Director, Market Access
Roche Tissue Diagnostics, USA

Senior Director, Head of Health Economics, Market Access & Policy Affairs Europe, Middle-East and Africa
Fresenius Medical Care, Germany

Global Director Scientific Communications | Medical Affairs
Medtronic, France

Program Director
Medtech4Health, Sweden

Sr. Consultant Health Economics, MD squared
Professor & Head of Health Economics & Healthcare Management Division, Kozminski University

Senior Vice President, Global Market Access
Inspire Medical Systems

Senior Director DACH, Payers & Health Economics
Coloplast

Senior Manager, Global Pricing & Competitive Portfolio Analytics Team
Philips Healthcare

Sr. Director Marketing & Academy Europe
Arjo, Europe

Hospital Economics - Sr. Manager Strategic Marketing  Monitoring & Analytics and Therapeutic Care
Philips, Germany

Director Reimbursement Germany
CytoSorbents Corporation

Ingmar Struss

Global Pricing Manager, SBU Oncology, Pharmaceuticals
Bayer, Germany

Experienced Solution Providers

CEO and Founder
ValueConnected

Director of European Operations
ValueConnected

President
Boston Healthcare, USA

Vice President
Boston Healthcare

Principal and Founder
Hull Associates

Director, Life Sciences
Huron Consulting

Event Structure

Photo Gallery

Event Program

MEDTECH: INTERNATIONAL PAYER & HTA FORUM

Day 1 - 3rd December, 2018

Stream Overview

Global healthcare systems are evolving daily. At a time of increased health economic reform, ageing populations and budget austerity, leaders in medical technology look to achieve optimal market access and commercialization of their products. As payers worldwide demand more value for money on the medical devices they fund, the importance of achieving patient access by demonstrating cost effectiveness and enhanced health outcomes is of the utmost importance. With payers in both developed and developing countries under extreme budgetary pressure, we will provide a platform for attendees to examine how health technologies are assessed, tough decisions are made and how we define “value”. This exclusive forum is the opportunity to meet and network with a broad spectrum of senior representatives who wish to encourage innovation whilst managing a limited budget.

Registration & Coffee
08.30
10-Minute Mindfulness Session (Optional)
08.40
Chairperson’s Opening Remarks:
09.00

CEO and Founder
ValueConnected

PAYER & HTA VIEWS & EXPERIENCES

HTA and MDR + IVDR implementation
09.10
  • EUnetHTA: initiatives for exchanges with regulator
  • Collaboration with medical stakeholder: European Society of Cardiology (ESC)

Director, Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA), Austria
Member, EUnetHTA

A NICE perspective of non-drug technology evaluation
09.40

Senior Scientific Adviser
NICE - National Institute for Health and Care, UK

MedTech services: Beyond product purchasing
10.10
  • The association’s approach for MedTech services: What are the main considerations?
  • Working with hospitals, clinics and manufacturers: How to impact wise decision-making?
  • Examples form different product areas

Head of Department of Economic Evidence-based Health Care
Main Association of Austrian Social Insurance Institutions

Networking & Coffee Break Sponsored by: Boston Healthcare
10.40
Med Tech companies transform from “suppliers” to “partners”. What’s next? Opportunities for new sources of value
11.10
  • Technology disruption: Non-healthcare players entering the market. Impact on our business model?
  • Technology-enabled care delivery: How do data, analytics and machine learning offer opportunities to address emerging payer and provider needs?
  • Reimaging the future state of med tech innovation: What kind of capabilities do we need to capture these new sources of value?
  • The case of diabetes management: Data at the center.
 

Director, Life Sciences
Huron Consulting

REGULATOR INITIATIVES

Highlighting the patient’s voice through mHealth technologies
11.40
  • How can healthcare authorities implement mHealth today and in the future?
  • What is the value for patients and budget holders?
  • How can patients be better heard and more involved in designing treatments and innovations?
  • The added value of mHealth: Data generation and data-driven innovation

Programme Officer European Commission eHealth, Well-being and Ageing (DG Connect)
European Commission

Panel discussion: The future of HTA for MedTech
12.10
  • On which product areas should national HTA agencies focus on?
  • What is the next step of HTA development in leading markets?
  • Which MedTech HTA models are the most successful?
  • Initiatives for regional / global co-operations and harmonization.
  • Is hospital level HTA the best way forward?

Director, Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA), Austria
Member, EUnetHTA

Senior Scientific Adviser
NICE - National Institute for Health and Care, UK

Senior Advisor
MedTech Europe

Senior Director, Head of Health Economics, Market Access & Policy Affairs Europe, Middle-East and Africa
Fresenius Medical Care, Germany

Luncheon Break Sponsored by: HULL Associates
12.50

INDUSTRY PERSPECTIVES & PRACTICES

Regional / European HTA collaborations for MedTech: Where are we now? Where are we going?
13.50
Jessica Imbert

Manager Market Access and Economic Policies
MedTech Europe, Belgium

Value-Based Healthcare (#VBHC) & Medical Devices: Aligning with payers on a common definition of value
14.20
  • Medical Device companies have rapidly progressed in the engagement of payers and non-clinical stakeholders, however there is still a critical need to do more and sell ‘solutions’ instead of products.
  • As an industry, there are some common ‘domains’ of value.  The gap between payers and manufacturers is not as big as we think.
  • The role of evidence in payer dialogue is growing.  However, lets ensure the right evidence is used, to ensure value claims move us from aspirational benefits to concrete patient outcomes.
  • Value based healthcare, and its key components have the ability to solve many of the largest challenges in healthcare: it digitally enables healthcare ecosystems, improves patient outcomes, and lowers total system costs.  What is the case AGAINST value-based healthcare?
  • A call to action:  moving away from ‘siloed submissions’, to ‘collaborative dialogue’:  enabling VBHC.

Director Value-Based Healthcare
ValueConnected

Designing evidence strategies for successful EU launches
14.50
The progression towards a pan-European HTA framework will pose new challenges to device and diagnostics companies as they contend with a heightened focus on higher quality evidence, with unchanged local decisionmaking around reimbursement.  This session will explore concepts in evidence development for medical technologies, and how European payment systems have evolved to demand greater clinical and economic value than ever before.  
 

Principal and Founder
Hull Associates

Networking & Coffee Break Sponsored by: ValueConnected
15.20
Innovations in the context of quadruple aim healthcare: HTA and beyond
15.50
  • Innovation inspired by the needs in the healthcare system.
  • Early evaluation of anticipated added value.
  • Assessment of outcomes and overall impact of the innovation.
  • Need to ‘co-create’ with relevant (internal and external) stakeholders.

Vice President, Innovation Program Manager
Philips Research

 

Maximizing Organizational Impact of the Market Access Function
16.20
  • Becoming an integral partner in strategic decision making.
  • Organizing in today’s value-based healthcare (VBHC) environment.
  • Case study: M&A.
  • Case study: Portfolio planning.

Vice President
Boston Healthcare

Panel discussion: Satisfying payer needs and building trust through value-based and other innovative access agreements
16.50
  • What can the industry do to better reflect the product’s value in the product’s dossier?
  • Overcoming measurement, monitoring & implementation difficulties in reality.
  • How can companies adjust their value demonstration in global markets? What are the different ‘’value’’ requirements in different markets?

Programme Officer European Commission eHealth, Well-being and Ageing (DG Connect)
European Commission

Associate Director of Medicines Optimisation, DGS & Swale CCGs
NHS

 

Director Value-Based Healthcare
ValueConnected

Vice President, Innovation Program Manager
Philips Research

 

Head of Department of Economic Evidence-based Health Care
Main Association of Austrian Social Insurance Institutions

Chairperson’s closing remarks
17.30
End of day one
17.40

18.30 - Exclusive Networking Dinner for Event Participants

MEDTECH: HTA-RELATED EVIDENCE DEVELOPMENT

Day 2 - Stream 1 - 4th December, 2018

Stream Overview

Medical device firms are increasingly under pressure from payers, HTA agencies, healthcare providers and other stakeholders to provide real evidence of their product’s benefit. Increasingly, especially when a technology is expensive, the CE Mark alone is no longer sufficient to gain market access. Robust health economic evidence demonstrating the clinical and economic value of a device is either becoming mandatory, or at least can be a source or competitive advantage to differentiate apparently similar products. Evidence can still be generated from scientific publications, but on top of this, sophisticated and expensive clinical trials and even real-world studies are now being designed and implemented. Getting the trial design right from the beginning is essential, so that the right research questions are being asked and robust methodologies are used to demonstrate improved health outcomes. Protocols must also be operationally feasible to ensure not just messy data is developed, but real evidence so that payers can gain insights into the value and make better reimbursement decisions. This stream will detail  how clinical, real-world, economic and scientific publication data sources can be integrated to prepare a sophisticated value dossier to demonstrate value to payers and other key stakeholders.

Registration & Coffee
08.30
10-Minute Mindfulness Session (Optional)
08.40
Chairperson’s Opening Remarks
09.00

Vice President
Boston Healthcare

Translating market needs into actual value stories
09.10
  • Identifying decision-makers’ needs
  • Assessing the relevant data to support claims
  • Building a concrete value story
  • Next steps: Teams, not tools, demonstrate value

CEO and Founder
ValueConnected

Italy: Evidence sources and market access for HTA used by Agenas
09.50
HTA Perspective
  • Sources of evidence for device assessment are numerous. However, as technology assessment is a multidimensional and complex activity no single source encompasses the whole evidence base needed. In addition, only few HTA agencies have access to registration dossiers.
  • The session will focus on the obstacles and opportunities to carrying out a fair assessment and the practical ways used by Agenas to overcome the problems.

Scientific Coordinator, Agenas HTA Projects
Agenas (Agency for Regional Health Services), Italy

Implementing hospital-based HTA as a part of the procurement process
10.30
Hospital Perspective

Head of Clinical Engineering Service
Humanitas Research Hospital, Italy

Networking & Coffee Break Sponsored by: HURON
11.10
Hospital-Based HTA Collaboration - Barcelona
11.40
  • Added value of proactively assessing technology in hospital context
  • Internal barriers & lessons learned from a manufacturer perspective
  • Important to have early dialogue and collaboration with such stakeholders

Senior Director, Head of Health Economics, Market Access & Policy Affairs Europe, Middle-East and Africa
Fresenius Medical Care, Germany

Clinical Evidence Generation: Combining MDR regulation requirements and market adoption
12.20
Regulations Impact
  • With the new regulation in the medical device industry, it is more important than ever to generate peer reviewed evidence to be able to tell a story of the medical device throughout its lifecycle
  • With market adoption perspective, there is a variety of studies to publish (from pre-clinical animal models to post-market studies)
  • This session will provide insights on how to create an evidence-based strategy throughout the lifecycle of the device thanks to teams’ cross functional collaboration and also possible challenges

Global Director Scientific Communications | Medical Affairs
Medtronic, France

Luncheon Break Sponsored by: IBM Watson Health
13.00

MEDTECH VALUE DEMONSTRATION

Triggering incremental funding for medical innovations
14.00
  • Are traditional reimbursement systems adequate for innovation?
  • Rewarding value, not only cost or evidence
  • Innovative Payment Mechanisms in Europe
  • Implications to Market Access Strategy

Director of European Operations
ValueConnected

How to develop a global clinical strategy that is efficient, yet meets the needs of key payers
14.40
  • Do we need ‘economic endpoints’ and a clinical focus on proving that new device therapy is cost efficient?
  • Do we need to focus on ensuring that we run randomized control trials that set the new therapy up against the standard of care solution? 
  • Do we need both approaches?

Senior Vice President, Global Market Access
Inspire Medical Systems

Networking & Coffee Break Sponsored by: PDCI
15.10
Generating and utilizing evidence from digital health for HTA
15.40

Sr. Consultant Health Economics, MD squared
Professor & Head of Health Economics & Healthcare Management Division, Kozminski University

Demonstrating the value of MedTech digital solutions to Payers and HTAs
16.10

Foundation Medicine Access Innovation and PHC Lead, Pharma International, F. Hoffmann-La Roche
Chair of the “Funding Medical Technologies” group, MedTech Europe

Demonstrating economic value to Hospitals: The Philips experience
16.40
  • Identify and focus on customer outcomes
  • Creating proof points that work in the ecosystem
  • Develop a value-based approach to overcome market access hurdles

Hospital Economics - Sr. Manager Strategic Marketing  Monitoring & Analytics and Therapeutic Care
Philips, Germany

Panel Discussion: Developing robust, quality evidence of a device‘s value
17.10
  • Data to evidence: What data sources are available that add value? (i.e. clinical, real-world, publications)
  • What data really makes a difference for external stakeholders to aid decision-making?
  • What can companies do to better develop evidence in a cost-effective manner?
  • Possible solutions to a lack of evidence

Scientific Coordinator, Agenas HTA Projects
Agenas (Agency for Regional Health Services), Italy

Global Director Scientific Communications | Medical Affairs
Medtronic, France

Sr. Consultant Health Economics, MD squared
Professor & Head of Health Economics & Healthcare Management Division, Kozminski University

Senior Vice President, Global Market Access
Inspire Medical Systems

Chief of development and communications
Center of Healthcare Quality Assessment and Control, The Ministry of Health of the Russian Federation

 

Chairperson’s Closing Remarks
17.50
End of Day Two
18.00

18.30 - Exclusive Networking Dinner for Event Participants - Sponsored by: Parexel Market Access

MEDTECH: PROCUREMENT & TENDERING EXCELLENCE

Day 2 - Stream 2 - 4th December, 2018

Stream Overview

Medical devices are coming under greater scrutiny by payers and hospital procurement directors than ever before. Manufacturers today are required to understand and quantify the cost savings for hospitals & payers based on the direct & indirect savings their products deliver. Changes to the European directives on public procurement are directly impacting the way medical device companies communicate and market their products via public procurement channels for high-value products. This one-day event will bring together procurement experts from European Policy-level, leading industry associations, hospitals (procurers) and the MedTech industry to join the conversation and to understand better the needs of their strategic partners. It will enable all participants the opportunity to benchmark procurement processes and tender approaches at a regional, local and hospital perspective. Medical device companies will understand in greater detail what their customers are looking for as drivers of value, and what is attractive for them to enhance their tender and public procurement strategy.

Registration & Coffee
08.30
10-Minute Mindfulness Session (optional)
08.40
Chairperson’s Opening Remarks
09.00

Director Value-Based Healthcare
ValueConnected

MEDTECH PROCUREMENT ENVIRONMENT

Current issues related to EU public procurement in the health sector
09.10

Legal & Policy Officer
European Commission

Hospital and primary care adaption of digital health technology: What impact will the deployment of digital technology have on healthcare and citizens in sparsely populated areas in the Nordics?
09.50
  • Are these markets early or late adopters?
  • Examples of adoption of MedTech

Director of Research and Education, Professor in Medical Biophysics
Region Jämtland Härjedalen, Östersund, Sweden

Value-based procurement best practices
10.30

Senior Advisor
MedTech Europe

Networking & Coffee Break Sponsored by: HURON
11.10
Bridging the gap: Best practices from a government founded national early access program accelerating the implementation of innovative medtech solutions in healthcare.
11.40
  • How Medtech4Health stimulates the implementation of innovations in healthcare
  • Results so far after three years
  • Hurdles and activities to overcome these
  • Linking economic value to the tendering process
  • Industry partnering with healthcare systems and academia to enhance health outcomes

Program Director
Medtech4Health, Sweden

Germany: The current procurement and tendering environment, ongoing debates and possible future scenarios
12.20

Senior Director DACH, Payers & Health Economics
Coloplast

Luncheon Break Sponsored by: IBM Watson Health
13.00
How to engage & communicate value to stakeholders?
14.00
  • Philip’s digital journey for the value calculator iPad solution: Lessons learned, dos and don’ts
  • What was the impact on stakeholder engagement in the procurement process

Senior Manager, Global Pricing & Competitive Portfolio Analytics Team
Philips Healthcare

Grow customer intimacy via new business modelling
14.40

Most MedTech companies operate in a commoditized business landscape, if you sell products it will always be about price. In order to grow in a sustainable way MedTech companies need to transform from suppliers into partners. It’s all about in detail understanding how products are being used, what the processes look like, how is care and cure being financed and what is the customers strategy. Only by understanding these components, the willingness to adapt the total offering and organization and having a long term view in mind, MedTech companies are able to grow their business in a sustainable way.

Sr. Director Marketing & Academy Europe
Arjo, Europe

Networking & Coffee Break Sponsored by: PDCI
15.20
Panel discussion: Shifting to Value-Based Procurement
15.50
  • How is value-based procurement viewed by external stakeholders?
  • How can ‘’added value’’ be demonstrated and is it a factor for payers?

Legal & Policy Officer
European Commission

Senior Advisor
MedTech Europe

Program Director
Medtech4Health, Sweden

Senior Director DACH, Payers & Health Economics
Coloplast

Sr. Director Marketing & Academy Europe
Arjo, Europe

Chairperson’s closing remarks
16.40
End of day two
16.50

18.30 - Exclusive Networking Dinner for Event Participants - Sponsored by: Parexel Market Access

MARKET ACCESS FOR PRECISION MEDICINES & IN-VITRO DIAGNOSTICS

Day 3 - Stream A - 5th December, 2018

Stream Overview

As the product nature of personalised medicines and companion diagnostics becomes increasingly complex, so too is the market access process surrounding these essential tests and procedures. These diagnostics bring unique market access & procurement challenged through DRG coding, bundling and procurement for laboratory test service providers. As the cost of these tests increases, so too does the requirement to justify the value and ROI to all necessary stakeholders. For companion diagnostics, partnering and strategic alliances with pharma (if not already vertically integrated) provides a strong market access vector, but achieving this has been proven difficult with only a handful of successful examples to date. As payers, procurers, HMOs and purchasers demand more evidence to justify costs, the challenges surrounding market access have never been greater. This one-day stream will discuss the market access challenges affecting personalised medicine and companion diagnostics globally with case studies of successful launches and cautionary tales of those which were not, to provide benchmarking and learning opportunities for all participants.

Registration & Coffee
08.30
10-Minute Mindfulness Session (optional)
08.40
Chairpersons Opening remarks
09.00

President
Boston Healthcare, USA

Companion diagnostics: Global overview
09.10

Foundation Medicine Access Innovation and PHC Lead, Pharma International, F. Hoffmann-La Roche
Chair of the “Funding Medical Technologies” group, MedTech Europe

HTA experiences with evaluating In Vitro diagnostics and personalised medicines
09.50

Associate Professor, Economic Evaluations in Health Care
Erasmus School of Health Policy and Management (ESHPM)
Institute for Medical Technology Assessment (iMTA)

Erasmus University Rotterdam, Netherlands

Networking & Coffee Break Sponsored by: Valid Insight
10.30
The importance of developing a market access strategy as an integrated part of product development
11.00
  • Identify market access process issues in the development of a product.
  • Defining and applying strategic value frameworks to engage key stakeholders.
  • Understanding the application of data for valued based business decisions 

Senior Director, Market Access
Roche Tissue Diagnostics, USA

Precision medicine becomes reality—tumor type-agnostic therapy
11.40
  • What is the value for patients, providers and HTAs & payers?
  • Why a paradigm shift to evaluating tumor agnostic precision medicine is needed.
  • Strong partnering with the Health Care System is key to facilitate the paradigm shift.
Ingmar Struss

Global Pricing Manager, SBU Oncology, Pharmaceuticals
Bayer, Germany

Panel discussion: Funding channels for precision medicines and companion diagnostics
12.20
  • Public & private payers, hospitals & HTA agencies: What makes them prioritise companion diagnostics in their reimbursement decisions?
  • The impact of diagnostics / pharma partnerships on market access
  • Ways to demonstrate value: Data generation, economic modeling, stakeholder communication

Senior Director, Market Access
Roche Tissue Diagnostics, USA

Foundation Medicine Access Innovation and PHC Lead, Pharma International, F. Hoffmann-La Roche
Chair of the “Funding Medical Technologies” group, MedTech Europe

Ingmar Struss

Global Pricing Manager, SBU Oncology, Pharmaceuticals
Bayer, Germany

Luncheon Break
13.00

SURGICAL & IMPLANTABLE DEVICE MARKET ACCESS

Day 3 - Stream B - 5th December, 2018

Stream Overview

Surgical device reimbursement & market access now requires more data and value justification than ever before. The good news is that with value adding benefits (minimally invasive procedures; less frequent implant replacement; faster recovery times and greater long-term health benefits), manufacturers have a real opportunity to show what their product can deliver in terms of cost effectiveness to HTAs & Payers. The requirement for existing products to defend their place in the market as well as new products to show true innovation is now a reality. With the data alone now telling the story, it provides large medical device manufacturers the ability to permanently solidify their place in the market and it gives smaller device companies the ability to break into this massive marketplace. This one-day stream will give best practice examples on value demonstration and market access approaches for surgical devices and implantables.

Registration & Coffee
08.30
10-Minute Mindfulness Session (optional)
08.40
Chairpersons Opening remarks
09.00

Principal and Founder
Hull Associates

How to apply a cost-effectiveness framework for the assessment of the incremental value of surgical medical devices?
09.10
  • How to define the incremental value of medical devices in the absence of randomised clinical trials?
  • Do we really need efficacy data for the assessment of effectiveness of medical devices?
  • How to account for healthcare professional-driven performance of medical devices in the cost-effectiveness analysis?

Sr. Consultant Health Economics, MD squared
Professor & Head of Health Economics & Healthcare Management Division, Kozminski University

Enabling value selling for Surgical & Implantable Devices
09.50
  • What is the role of market access in economic selling?
  • The challenge of quantifying value.
  • Building effective tools and training methods.
  • Partnering with commercial teams.
  • Case studies: Selling value in the UK and Germany.

CEO and Founder
ValueConnected

Networking & Coffee Break Sponsord by: Valid Insight
10.30
Market access for surgical & implantable medical devices in Latin America
11.00
  • Market access as part of a cross-functional company’s strategy.
  • The way forward with external stakeholder’s engagement: payers, HTA agencies, doctors and patients.
  • Value-based healthcare trends and practices

Vice President Communications, Europe, Middle East & Africa
Medtronic

Health economic modeling for an innovative therapy
11.40
  • Strategic European health economic modeling approach
  • Using health economics as a sales tool

Director Reimbursement Germany
CytoSorbents Corporation

Panel Discussion: Re-defining ‘’value’’ for surgical & implantable devices
12.20
  • What has changed in the payer’s definition of ‘’value’’? What is the impact on the industry?
  • How are value-based access models being viewed by external stakeholders?
  • Building a value proposition in different lifecycle stages.

Vice President Communications, Europe, Middle East & Africa
Medtronic

Sr. Consultant Health Economics, MD squared
Professor & Head of Health Economics & Healthcare Management Division, Kozminski University

CEO and Founder
ValueConnected

Director Reimbursement Germany
CytoSorbents Corporation

Luncheon Break
13.00

MOCK PAYER PANEL WORKSHOP

Day 3 - 5th December, 2018

Stream Overview

Before our panel of Subject Matter experts and practitioners, participants will prepare short briefs to demonstrate the value of several fictional case study products to a panel for approval.
As all MedTech market access industry practitioners know, you only get one chance to make a great first impression on payers and procurement decision makers, so this workshop will allow participants to practice their presentations in a safe environment. Assessors will look at: Content, Presentation skills, Style and Evidence Use in order to give constructive feedback.
Participants will be grouped into product specific areas which will enable them to tailor their learnings for their products, including:

- Diagnostic Imaging/Capital Equipment  (Robotic Surgical Device & HemoDialysis Machine
- Surgical & implantable devices              (Transarterial Valve Replacer & Femoral Stem Implant)
- Hospital Consumables                           
(CSII Insulin Pump & Companion Diagnostic)

Participants will compose and deliver presentations to our panel of Payers/Purchasers to bring the learnings all together.

Chairperson's Opening Remarks:
13.50

Principal and Founder
Hull Associates

Payer Panel Brief and words of wisdom from Advisors when presenting
14.00

Associate Director of Medicines Optimisation, DGS & Swale CCGs
NHS

 

Scientific Coordinator, Agenas HTA Projects
Agenas (Agency for Regional Health Services), Italy

Member
RWE4Decisions - RIZIV/INAMI led HTA/Payer Initiative

Senior Director, Head of Health Economics, Market Access & Policy Affairs Europe, Middle-East and Africa
Fresenius Medical Care, Germany

Senior Health Economist
Health Technology Wales, UK

Breakout: Case Study 1 – High Value, Innovative Product Examples
14.30

Participants will be given a fictional product to develop an argument for, to present to our panel of Payers, based on the product area best suited to their daily practice

Area 1: High Value Diagnostic & Capital Equipment - PICASSO
Area 2: Surgical & Implantable Devices - TVAR
Area 3: Hospital Consumable/OTC Devices - CONNEX insulin Pump

Mock Payer/Procurer Panel – Case Study 1 with Feedback
15.15
Networking & Coffee break
15.45
Breakout: Case Study 2 – Lower Value, Mature Market Product Examples
16.00

Participants will be given a fictional product to develop an argument for, to present to our panel of Payers, based on the product area best suited to their daily practice

Area 1: High Value Diagnostic & Capital Equipment - Reno-Matic Home Dialysis Machine
Area 2: Surgical & Implantable Devices - Fem-X Femoral Stem
Area 3: Companion Diagnostic

Mock Payer/Procurer Panel – Case Study 2 with Feedback
16.45
End of day three
17.15

Device manufacturers & distributors:
Marketing, Market-access, Business Development, Country Managers, Health Economics, Pricing & Reimbursement, Government & Stakeholder Relations, Regulatory Affairs

Stakeholders:
Health Plans & Insurers, Payers, Health Technology Assessors, Hospitals, Health Ministry, Regulatory Agencies, Independent Health Economists, Academics, Physicians and Patient Groups

Solution providers & consultants:
CEOs, Business Development, Senior Consultants, Global and Regional Heads, Independent Academics, Health Economists

The MedTech Access Leaders Forum will also have the PharmAccess Leaders Forum co-located. That event is for senior directors of Market Access at pharma and biotech organisations and will have a specific focus on Specialty Pharma products, Innovative Market Access Agreements and Precision Medicine Market Access. It will also feature a Mock Payer Panel Workshop with Real Payers giving feedback to participants and an additional workshop on Managed Entry Agreements & Risk Sharing approaches. For more information click the banner below:

Event Partners

This event is accredited for CPD (Continuing Professional Development) status

RECEIVE DISCOUNTED FLIGHTS WHEN YOU REGISTER FOR THIS EVENT WITH

Speaker Biographies

Birgit Morlion

Programme Officer European Commission eHealth, Well-being and Ageing (DG Connect)
European Commission

Birgit Morlion is an engineer (PhD) with a mission to make digital health come true. Over the last 15 years she has been actively involved in eHealth research and facilitating the adoption of digital innovation in health care in Belgium. She was part of the start-up team of the Flemish digital research and innovation institute iMinds; helping to bridge the gap between research and exploitation of results. She also occupied strategic advisory roles for the Flemish and the Belgian Ministers of health in the domain of medical data-exchange and patient access to electronic medical records. In May 2017 she joined the eHealth, well-being and ageing unit of the European commission (DG Connect) where she works on the digital transformation of health and care in the Digital Single Market more specifically with a focus on mobile health (mHealth), integrated care and active and assisted living.

An Baeyens

Legal & Policy Officer
European Commission

An holds a Belgian law degree issued by the University of Leuven as well as a master of laws issued by the Albert-Ludwig University of Freiburg im Breisgau (Germany). Prior to the Commission An has worked in the area of health law, first an assistant at the University of Leuven and thereafter in the private sector. Since more than twelve years, An has been working for the Commission dealing with different internal market issues.  Since three years she works in the field of public procurement. In particular, she deals with Austrian and German complaints. She also is responsible for the policy work related to the application of public procurement rules in the health and waste management sector.

Claudia Wild

Director, Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA), Austria
Member, EUnetHTA

Claudia Wild was born in 1960. Studies of communications & psychology at the University of Vienna and of political sciences at the Ohio University in Athens/Ohio/USA. Graduation at the University of Vienna: Doctor of Philosophy in 1985. 1985-1988 Research Associate on “media impact on cognitions” at the Institute for Communications and Political Science at the University of Nuernberg/Germany and other freelance media impact research projects. 1989-2006: Senior Researcher at the Institute of Technology Assessment at the Austrian Academy of Sciences and development in the research field Health Technology Assessment in Austria. Since April 2006 she is Director of the Ludwig Boltzmann Institute for HTA. In 2009 habilitation/postdoctoral lecture qualification in social medicine (Medical University Graz) on the topic of “resource allocation in health-care systems”. She is member of several national and international organizations, teaches HTA at universities and private colleges and is an active reviewer for several international journals in the field of HTA.

Diar Fattah

Associate Director of Medicines Optimisation, DGS & Swale CCGs
NHS

 

Diar is the Associate Director of Medicines Optimisation at Dartford, Gravesham and Swanley and Swale CCGs. Diar takes the lead on the provision of medicines optimisation on all matters relating to medicines use, prescribing and the provision of pharmaceutical services to the CCGs. His interests have been focused on combatting inappropriate polypharmacy with the use of healthcare data analytics.

Diar also sits on the NICE technology appraisal committee, analysing HTA applications for the NHS.

Previously, he has worked as Medicine Optimisation Pharmacist at Medway CCG, a tutor at the Centre for Pharmacy Postgraduate Education (CPPE) based at the University of Manchester and a pharmacist clinical advisor in NHS 111.

Diar holds a Masters in Pharmacy and a Masters in Health Economics and Health Policy."

Chris Chesters

Senior Scientific Adviser
NICE - National Institute for Health and Care, UK

Chris currently works in the Scientific Advice team at NICE which provides advice helping companies to prepare for NICE evaluations and to support discussions with payers and commissioners to enable market access. He has also previously worked in the NICE medical technologies evaluation programme (MTEP) and the technology appraisals programme (TAP). Chris also has experience working in a healthcare consultancy where he worked on a variety of health technology assessment and market access projects. Chris has a Master’s degree in Biological Chemistry from the University of Sheffield, and completed a PhD in biological sciences from the University of Manchester.

Tom Jefferson

Scientific Coordinator, Agenas HTA Projects
Agenas (Agency for Regional Health Services), Italy

Tom Jefferson is a physician, epidemiologist and researcher. Tom’s field of expertise is evidence synthesis applied to Cochrane and other systematic reviews and Health Technology Assessment.  Tom is a Senior Associate Tutor at the University of Oxford, a researcher at the Nordic Cochrane Centre and the scientific coordinator for the production of HTA reports on non-pharmaceuticals for Agenas, the Italian National Agency for Regional Healthcare.

Göran Larsson

Director of Research and Education, Professor in Medical Biophysics
Region Jämtland Härjedalen, Östersund, Sweden

Göran Larsson has a Ph.D. in medical biophysics from Umea University. After his Ph.D. Göran joined University of Cambridge, UK for a three year Post.Doc period. In 2004 he returned to Umea University where he worked as a university teacher and researcher until 2012 when he moved to Östersund for his current position as Director of Research and Education in Region Jämtland Härjedalen. In 2014 he become Professor in medical biophysics. Göran Larsson is interested in eHealth/mHealth solutions and is responsible for innovation processes related to digitalization of healthcare in his organization.

Paolo Oliva

Head of Clinical Engineering Service
Humanitas Research Hospital, Italy

Paolo joined Humanitas Research Hospital in July 2017. He graduated from University of Naples Federico II with a Bachelor’s degree in Biomedical Engineering. He completed his Master’s degree in Clinical Engineering at the same University and subsequently completed his second level Master’s degree in Health Economics at SDA Bocconi School of Management. Prior to joining Humanitas Research Hospital, Paolo worked for 3 years as Clinical Engineer and Operation Manager at PLV Fatebenefratelli private Group of Hospitals.

Karen Facey

Member
RWE4Decisions - RIZIV/INAMI led HTA/Payer Initiative

Karen Facey has a PhD in Statistics and has worked as a senior statistician in pharmaceutical companies and the MHRA, the UK medicines regulatory agency. In 2000 she was founding Chief Executive of the first national health technology assessment (HTA) Agency in Scotland and since 2003 has been an independent consultant on HTA and patient involvement. She has been a board member of a health board (payer/provider) in Scotland and is a member of the Scottish HTA appraisal committee for non-medicines HTA. She pursues research interests as an Honorary Research Fellow at the University of Edinburgh in assessment of therapies for rare diseases and Managed Entry Agreements. She is part of the ORPH-VAL working group including regulators, HTA experts and industry. Karen is lead editor on a book on patient involvement in HTA published by Springer in May 2017 and in 2014 she was named in the top 100 practicing scientists in the UK.

Nuriya Musina

Chief of development and communications
Center of Healthcare Quality Assessment and Control, The Ministry of Health of the Russian Federation

 

Dr. Musina is a Chief of Development and Communications at the Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation. 

Dr. Musina is also an Associate Professor at the Department of Pharmacology Sechenov University. Dr. Musina was a postdoctoral fellow and obtained a Master of Science Diploma in Economic Evaluation for Health Technology Assessment at the University of York, UK (2016). 

She’s an author of educational and methodical manuals for pharmacists and more than 30 research publications, she is also a member of the editorial board of the scientific journal "Pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology".

Leona Hakkaart-van Roijen

Associate Professor, Economic Evaluations in Health Care
Erasmus School of Health Policy and Management (ESHPM)
Institute for Medical Technology Assessment (iMTA)

Erasmus University Rotterdam, Netherlands

Dr Hakkaarts’ interest in the relation between cost and effects in health care is the result of a broad interest to explore economic evaluations from a societal perspective and report outcomes that helps decision making in health care on different levels. She was involved in the developed questionnaires to measure cost from a societal perspective. The iMTA Medical Cost Questionnaire (iMCQ), the iMTA Productivity Cost Questionnaire (iPCQ) and the Treatment inventory of Costs in Psychiatric Patients (TiC-P) were developed. Her special interest is to develop a research program for economic evaluations in mental health care and orphan diseases. Therefore, she works closely with a large number of other national and international institutions. Dr Hakkaart supervises PhD students on this topic. She is co-promoter of a PhD student conducting cost effectiveness analyses on orphan drugs. Recently, she supervised the update of the Dutch manual for costing studies in economic evaluations supported by the National Health Institute (ZiN). A collaborative partnership with TOPGGz, a foundation for highly specialized psychiatric care, was initiated. In this context, she developed a method to develop ‘Decision Tools’ (DT) to identify severe and complex patients for top clinical specialized care. Validated DTs for personality disorders, eating disorders, depression and anxiety were developed. She guides and teaches Bachelor and Master students in economic evaluations.

Tom Winfield

Senior Health Economist
Health Technology Wales, UK

Tom specialises in economic modelling and has interests in the health econometrics of advanced therapies, he leads the health economics team at health technology wales. Within HTW he is responsible for the development and delivery of the technology evidence appraisals which lead to national guidance reports. Tom is currently evaluating the optimisation of cancer treatment pathways and is developing market access strategies for cell and gene therapies. Previously he worked for the Swansea Centre for Health Economics performing HE evaluations alongside clinical trials. He has qualifications in Economics from Swansea university (BSc , MSc, PhD) and in health economics (PGCert) from Aberdeen University.

Gottfried Endel

Head of Department of Economic Evidence-based Health Care
Main Association of Austrian Social Insurance Institutions

Gottfried Endel, M.D., is the Head of the department of Evidence Based Health Care in the Main Association of Austrian Social Insurance Institutions. He joined the Austrian Social Insurance Authority for Business (SVA) in 1988 and served in the department for Prior Authorization and Physicians’ Control. Gottfried is a General Practitioner since 1988.

Yves Verboven

Senior Advisor
MedTech Europe

Graduated in 1987 as Electro-Mechanical Engineer with specialty electronics at the Catholic University of Leuven,  followed by a post-graduate year of Master of Business Administration. A first working experience in the field of Clinical Engineering at Intermedics, a US based pacemaker and implantable defibrillator company. Build out and directed the European Clinical Research Department. Holder of 5 patents in field of cardiac stimulation in health failure and co-author of 3 publication in this period. Joined in 1999 Medtronic to head the European Heart Failure clinical outcomes & research department ensuring the development of Clinical and Health Economic Outcome Evidence. In close cooperation with Clinical Community landmark trials were designed, conducted and published  in the Int’l journals as New England Journal of Medicine, Circulation and others with a high impact factor. A contribution of to 8 publication of which 3 as co-author. This evidence based ensured : Cardiac Resynchronization therapy obtained a class I indication level of evidence A in clinical guidelines; Cardiac Resynchronization therapy obtained a positive HTA appraisals for the full population studied . In September 2008, took on the responsibility of Assistant Director Health Economics, EurMEA at Alcon in the field of Ophthalmology for both medicinal and medical devices ranging from treatments of bacterial conjunctivitis, dry eye and glaucoma to Implantable Ocular Lenses. Developed comprehensive Patient Report Outcomes instrument to support patient diagnosis and assessing the outcome value of dry eye treatment to patients. Supported and co-authored to an additional 8 publications. As of 1st May 2012, head of Market Access and Economic Policies for  MEDTECH EUROPE to strive to balanced pro-innovation policies and to shift to a Value based Access model within EU frameworks.  Initiatives in dialogue with  procurers, payer, HTA member states representatives and other stakeholders are MEAT Value Based Procurement, Value of Diagnostic Information,  Modern HTA Cooperation in Europe,  new evidence and financing schemes to shift to access of medical technologies of value for patients, healthcare, society and our economy.

Richard Charter

Director Value-Based Healthcare
ValueConnected

Richard has over 15 year of industry experience across both the Healthcare and Financial services sectors. Richard is currently the Director of Value Based Healthcare at ValueConnected, a company focusing on implementing Value Based Healthcare.  Richard was formerly at Becton Dickinson, where held various senior roles in Market Access & Pricing.  Richard is currently the Co-Chair of the ISPOR Medical Devices Interest Group, where he also teaches the short course on Market Access for Medical Devices.  Richard is also the co-chair of HTAi Medical Device Interest Group, where he is frequently called on as a guest speaker.  Richard is currently the industry Advisor to COMED, an EU funded consortium measuring outcomes and costs in medical devices.  Richard graduated from SDA Bocconi in Italy with a Masters in Healthcare Management, Economics & Policy, as well as from the University of Guelph in Canada, in Management Economics & Public Policy.

Hans Hofstraat

Vice President, Innovation Program Manager
Philips Research

 

Hans Hofstraat is Innovation Program Manager at Philips Research, a position he has held since 2009. As Innovation Program Manager, Hans works with teams within Philips Research, and with colleagues in Business and Markets, on innovations in the area of Oncology, Neurology, and Universal Access to Care, combining deep clinical insights with the opportunities offered by digital healthcare. Together with partners within and beyond Philips, Hans is passionate about identifying major needs in the health-technology domain, and to address these by developing meaningful solutions underpinned by proven outcomes. His aim is always to achieve innovations that broaden access to appropriate care and improve quality of life for patients and healthcare professionals.

Hofstraat holds several positions in (inter)national advisory bodies. Amongst others, he is a member of the Dutch Sounding Board for Horizon 2020, contributing to work on Health, Demographic Change and Well-being. He is a member of the Steering Committee and co-initiator of the big data initiative of Top Sector Life Sciences & Health. He is also a member of the Management Team of the Institute for Diagnostic and Interventional Imaging (IDII), in which Philips participates together with UMC Utrecht, University Utrecht, and TU Eindhoven. He is a member of the Supervisory Board of the European Institute of Innovation & Technology (EIT) Health, and a member of the European Scientific Panel for Health.

Hans joined Philips Research from Akzo Nobel Central Research in 1998. He has also worked as a (part-time) Professor at the Institute of Molecular Chemistry of the University of Amsterdam, and at the Public Works Department of the Dutch Ministry of Transport and Public Works in The Hague. He graduated with a PhD in physical chemistry from the Free University Amsterdam (thesis awarded with the Royal Dutch Shell prize), and was a post-doc at the Eidgenössische Technische Hochschule, Zürich, Switzerland. He worked as a lecturer at the Free University, the Free University Medical Center, and the University College of Swaziland in Kwaluseni while completing his studies. Hans has authored about 200 publications with an h-index of 42 (Google Scholar) and holds 10 granted US patents.

https://www.linkedin.com/in/hofstraat/

Markus Ott

Foundation Medicine Access Innovation and PHC Lead, Pharma International, F. Hoffmann-La Roche
Chair of the “Funding Medical Technologies” group, MedTech Europe

Markus A. Ott is a Global Medical Technology Professional with more than twenty years successful experience in international/global commercial & non-commercial roles he has become a highly effective and creative industry leader with extensive knowledge of the healthcare market.

Currently he is leading the Market Access & Health Policy department at Roche Diagnostics International (CPS) based in Rotkreuz/Switzerland.

His passion are all aspects of his job but primarily Value Based Healthcare & the digitalization of our industry.

He is/has been a member of global Management teams for various companies and associations. So, Markus has been member of the Executive Board of MedTech Europe as well as the Swiss Diagnostic Association. He acted as Chair Elect and Executive Board Member of EPPOSI (European Platform for Patient's Organizations, Science & Industry). Currently he chairs the HTA IVD & Value of Diagnostics Working groups @ MedTech Europe.

Finally, he is author of multiple publications as well as chair, panelist and speaker at many global conferences.

Rafael Casas-Don

Vice President Communications, Europe, Middle East & Africa
Medtronic

Creative, international and multi-cultural business, communications and public affairs executive, lawyer and entrepreneur with results-driven management experience in business development, corporate and public affairs, government relations, corporate social responsibility, crisis management, branding and positioning, stakeholder engagement, product and corporate marketing, across industries-- from healthcare to not-for profit. Specialties: Strategic corporate communications, corporate affairs, government relations, crisis and issues management, perception management, employee and change management communications, media relations, marketing communications, labor relations, industry engagement, corporate responsibility, compliance communications, issues advocacy, multicultural communications.
Currently working as Vice President Market Access, Latin America at Medtronic. Previously worked as Vice President of Public Affairs and Director Communications Latin America Region at Baxter, and had several managing positions at Burson-Marsteller in past.

Elizabeth Sheppard

Senior Director, Market Access
Roche Tissue Diagnostics, USA

Elizabeth received her undergraduate degrees at State University of New York and Master’s of Business at Wake Forest University – Babcock school of Business. She is currently Head of Global Market Access, Roche Tissue Diagnostics in Tucson, Arizona. She provides leadership oversight of Market Access projects, strategic health economics and pricing, reimbursement support for Roche affiliates concentrating on high medical value assays.  She also oversees access management of External Quality Assessment program participation, and relevant guidelines and standards. Prior to her current role she has held other key positions within RTD that included launch optimization and commercialization of new FDA approved products.

 

Elizabeth has authored numerous publications and is frequent invited speaker at state, regional, national and international congresses. She is a voting member and committee representative with the Clinical Laboratory Standards Institute (CLSI) and member of the ISO/TC212 Clinical Laboratory Testing and in vitro Test Systems, US Technical Advisory Group, Advisor Histotechnology Committee, College of American Pathologists (CAP), board member of the Arizona Bioindustry Association and President of the Anatomic Pathology Patient Interest Association (APPIA).

Christian Apel

Senior Director, Head of Health Economics, Market Access & Policy Affairs Europe, Middle-East and Africa
Fresenius Medical Care, Germany

Christian has an academic background in human medicine, biomedical sciences, health policy & health economics. Before joining Fresenius Medical Care, Christian worked in different strategic and management positions of a medium sized care provider in Germany. In Fresenius Medical Care he is heading the Health Economics, Market Access & Policy Affairs activities for Europe, Middle-East and Africa.

Patrice Becker

Global Director Scientific Communications | Medical Affairs
Medtronic, France

Patrice is a medical device industry expert with 25 years of experience in Clinical and Medical Affairs. He holds a Masters Degree in Pharmacology and a Masters Degree in Business Administration for Pharmaceutical and Biomedical Companies. After he joined Sofradim/Medtronic in 1998, he took the lead and established the clinical research department. Since 2012, he is the Leader of the Scientific Communication for Abdominal and Robotic Surgery. Prior to joining Medtronic, he spent almost 5 years as a clinical research manager at Biomatech, a consulting and testing company focused on medical devices. In addition, Patrice was an expert in numerous standards including ISO 14155, Medtech, and was a member of several task forces.

Reidar Gårdebäck

Program Director
Medtech4Health, Sweden

Mr Gårdebäck program director for the Swedish National Strategic Innovation program Medtech4Health which focus on financing of innovative projects and strategic collaborations, nationally and internationally within the medtech area.  By acting as catalyst, Medtech4Health seek to encourage the increased implementation of medical technical solutions in healthcare, make healthcare more effective, and strengthen the Swedish medtech industry. This is done through awarding funding to different projects, through strategic investments, and by lobbying at different levels both inside and outside Sweden. The program is governemnet founded through the Swedish Innovation Agency VINNOVA and have a financing budget around 6 Million Euro / year.

Mr Gårdebäck has more than 25 years of experience in global international medtech companies like Siemens, Elekta, GE Medical systems and Medtronic.  The last two Mr Gårdebäck held the position as CEO for the business in Sweden.  He is also board member in several companies and has a technical degree as Master of Science in Physics from KTH, the Royal Institute of Technology. In addition to general management positions Mr Gårdebäck have experience working in R&D departments as well as project management and marketing & sales positions including tendering and healthpolicy related activities.

Katarzyna Kolasa

Sr. Consultant Health Economics, MD squared
Professor & Head of Health Economics & Healthcare Management Division, Kozminski University

Driven with the passion to health economics, I have more than 20 years of academic and industry experience in the field of healthcare. Holding various Regional and Global leadership positions, I have been working extensively within public health sector as well as pharma and medtech industry.

After six years employment at the Kalmar County Council in Sweden, I held global and regional Health Economics & Outcomes Research (HEOR) positions at AstraZeneca and BiogenIdec respectively. At Bristol Myers Squibb and Lundbeck I lead Market Access teams in Central Eastern European (CEE) and Nordic Region. In the last five years, I gained experience with the pricing &reimbursement challenges in the field of medical devices. I supported Straub Medical as Global Market Access Lead. Before that, I was Senior Sales Director responsible for HEOR at GE Healthcare.

Since 2018 I am a Professor at the Kozminski University heading Health Economics & Healthcare Management Division (HeM). I am the leader of the International Master Program Health Economics & Big Data (HEBDA) financed by the EU research grant. In October 2020, I was nominated to  the ISPOR’s Health Sciences Policy Council (HSPC). Since January 2020, I am chair elect of ISPOR Special Interest Group Digital Health as well.

My biggest strength is the market access planning for a successful pricing & reimbursement strategy. Knowledgably of HTA guidelines, DRG financing and hospital procurement pathways across EU & US settings, I will be able to advice on the optimal market entry that ensures the best differentiation of a given technology against alternative treatment options

Kathy Sherwood

Senior Vice President, Global Market Access
Inspire Medical Systems

In 2017, Kathy joined Inspire Medical Systems, a manufacturer of an implantable hypoglossal nerve stimulation device for treatment of obstructive sleep apnea, to lead the Reimbursement and Market Access function. 

She has over 25 years of Medical Device industry experience and has led reimbursement teams both in Europe and the US.  Prior to joining Inspire, Kathy lead US reimbursement and pricing teams for Boston Scientific, St. Jude Medical, and Medtronic.  She lived in the Netherlands for several years, leading KCI Medical’s European reimbursement function.

Kathy holds a Bachelor of Science degree in Mechanical-Industrial Engineering from the University of Illinois, Urbana-Champaign, and an MBA from the University of Minnesota, Carlson School of Business in Minneapolis.   

Christian Grete

Senior Director DACH, Payers & Health Economics
Coloplast

Christian spent the first half of his career in the German Statutory Health Insurance, covering different positions and ended up with the project lead of one of the first huge Managed Care models in the country. As a consultant, Christian supported sickfunds to introduce the German DRG system and Managed Care approaches before he started with his first market access projects. Prior to joining Coloplast in 2017 he held different national and international market access positions at Johnson & Johnson, Accuray and in a pharmaceutical startup. Christian holds a Bachelor of Science degree in Health Communication and Healthcare Management. As a Director Payers & Health Economics at Coloplast, Christian is now responsible for Regulatory Affairs, Public Affairs and Payer Managenment.

Tobias Happel

Senior Manager, Global Pricing & Competitive Portfolio Analytics Team
Philips Healthcare

After finishing his European Finance and Accounting studies in Bremen, Germany (Dipl.-Betriebswirt) and Leeds; England (BA (Hons)) plus obtaining an MBA in Edinburgh (Scotland), Tobias Happel worked for almost 2 years as a consultant for financial Application at Oracle. For the last 17 years he was in different finance and pricing roles at Philips Medical in Böblingen (Germany) with growing responsibilities ending up in a global pricing responsibility in the Value Segment Solutions Equipment and MR Patient Care.  In 2014 he was accredited as Certified Pricing Manager from the European Pricing Platform. Besides that, for the last 18 months he also led a value based pricing project in the MR Patient Care environment and is adapting some key learnings to other strategic value based pricing projects.

Jan van Megen

Sr. Director Marketing & Academy Europe
Arjo, Europe

Jan joined Arjo in January 2011 as Sales and Marketing Director for Arjo Netherlands. In 2015 Jan was appointed Country Manager Netherlands and in 2016 Managing Director BENELUX. In this position Jan grew the business and strengthened customer intimacy by the development of new business models like Pay per Patient, a customer web portal, track and trace solutions and consultative selling based on solutions. Jan holds a Commercial economics degree from the University of applied science ‘s-Hertogenbosch, Netherlands and is a Registered Marketer certified by the European Marketing Certification Foundation.

Anne Jurine-Frank

Hospital Economics - Sr. Manager Strategic Marketing  Monitoring & Analytics and Therapeutic Care
Philips, Germany

Anne is currently working as a Hospital Economics Senior Segment Manager at Royal Philips in Germany. Her focus is to bring the voice of the economic stakeholders of the hospital in the solutions development, marketing and selling of the Monitoring & Analytics and Therapeutic Care businesses. She has been working at Philips for 6 years mostly in the marketing intelligence area and prior to that for other companies including Hewlett-Packard as a financial analyst at the start of her career. She holds a French Bachelor degree in Marketing and a Master in Business Administration with a major in finance from Cornell University.

Franziska Preissing

Director Reimbursement Germany
CytoSorbents Corporation

Being a marketing expert with over a decade of international experience in the medical device industry, Franziska Preissing has been able to gather extensive experience, particularly in the field of introducing innovative products and therapies into intensive care and cardiac surgery. In the position of International Marketing Director of several medical device companies, as well working as a consultant, she has, over the years, acquired profound knowledge on reimbursement strategies and health economics, with a focus on how to proceed as a small and medium sized enterprise. Today Franziska Preissing is responsible for global reimbursement strategies and health economics at CytoSorbents Europe, who launched the CytoSorb adsorber, an extracorporeal therapy that enables innovative adsorption in SIRS (systemic inflammatory response syndrome) and sepsis patients.

Ernesto M. Nogueira

CEO and Founder
ValueConnected

Ernesto is the Founder and Managing Director of ValueConnected. He has over 23

years of experience leading healthcare strategies to drive access and expansion for new products, developing value propositions for both public and private stakeholders and assessing global market opportunities. He has worked for both government agencies and global healthcare companies in roles ranging from strategic marketing and new product development to health economics and reimbursement. Ernesto has led several Market Access projects across Europe, US, Middle East and Latin America. Ernesto holds an MBA from the University of Texas at Austin and is fluent in English, Spanish and Portuguese.

Ben Modley

Director of European Operations
ValueConnected

Ben is the Director of European Operations at ValueConnected and has more than 10 years of extensive experience with both pre and post-launch activities, with a strong focus on health technology assessment, market assessment and purchasing processes. He has managed several international projects within Western and Eastern Europe.
He has performed numerous analyses to guide sales and pricing of medical technologies as well as reimbursement applications by using health economics to drive commercial messages. 
Ben has an in-depth knowledge about Germany, Switzerland and Austria with an extensive network of contacts with doctors, reimbursement authorities and purchasing departments within these countries. He graduated in Mathematics at the Albert-Ludwigs-Universität Freiburg im Breisgau in 2009 and is fluent in both German and English.

Joseph Ferrara

President
Boston Healthcare, USA

Mr. Ferrara has over 18 years of experience in life sciences consulting, working with biopharmaceutical, medical device, diagnostics, and health care IT clients in market and business development strategy. He leads the global consulting team with practice areas in reimbursement and pricing, health economics, market analysis, and business development strategy. Mr. Ferrara has extensive experience in the development of novel business approaches designed to capture evidence-based value for innovation health care technologies. Mr. Ferrara writes and speaks extensively on the subject of the value of medical technology innovation, with particular focus on pharmacogenomics, specialty pharmaceuticals, and novel therapeutic devices. Prior to his consulting role, Mr. Ferrara led a joint venture between Boston Healthcare and a non-profit research organization focused on a global electronic medical record network for the purposes of clinical trials and health outcomes research. Mr. Ferrara completed undergraduate studies at the University of Cincinnati and received a master’s degree from Harvard University.

Rob Wenthold

Vice President
Boston Healthcare

Mr. Wenthold has 15 years of experience providing consulting services to the biopharmaceutical, medical device and diagnostic companies on commercialization and market access strategy. Mr. Wenthold’s particular focus is global pricing, reimbursement, and market access for innovative medical technologies. He has substantial experience in global markets and managed Boston Healthcare Associates European HQ office in Berlin from 2013-2014. Mr Wenthold has been responsible for international operations since 2009. Mr Wenthold brings an in-depth understanding of global payers and health systems and a rigorous research methodology to properly assess investment opportunities and risks. He has experience supporting several due diligence transactions, embedding pricing and reimbursement risk, and building additional evidence investment and infrastructure development into go/ no-go and valuation decisions. He advises start-up and early stage companies as well as large multinationals and has experience across disease types, settings of care and global markets.

Stephen Hull

Principal and Founder
Hull Associates

Stephen Hull is Principal and Founder of Hull Associates LLC, a specialized global reimbursement and market access consultancy. He and his firm leverage over 25 years of experience in US and global reimbursement and in-market expertise on behalf of pharma, medical device and diagnostics Clients. Prior to forming Hull Associates in 2007, he served as SVP for Global Reimbursement at AdvaMed, in Washington, D.C. and as chair of the ISPOR Medical Devices Council. Stephen holds a Master’s degree in health policy from the Johns Hopkins Bloomberg School of Public Health, and a bachelor’s degree in international relations and French from Colgate University.

Sotiris Rompas

Director, Life Sciences
Huron Consulting

Sotiris has been working with market access, marketing and policy teams of Fortune 500 Life science companies to assess health system trends and stakeholder needs, develop value propositions for innovative medical technologies and develop Access strategy.
Prior to joining Huron, Sotiris held senior positions at Boston Healthcare Associates and GfK Market Access where he lead teams on various commercial, pricing & market access and marketing engagements at the product- and portfolio- level. 
Sotiris started his consulting career at IMS Consulting group working in the Pricing and Market Access practice.
Sotiris has expert working knowledge in various quantitative and qualitative methodologies and research tools (e.g., conjoint, MaxDiff, MCDA, virtual ad boards, IDIs, scorecards).

Focus areas
• Access strategy
• Payer and Provider dynamics
• Value proposition development
• Innovative Business models

Education
• PhD in Strategic Management, Warwick Business School (Economic & Social Research Council fellow)
• M.Sc. International Health Management, Imperial College London

Previous Attendees at MedTech Access Leaders Forum - Berlin, Germany, 2017

Company
Job Title
3M
Scientific Business Manager-West Europe
Abbott Diabetes Care
Global Market Access
Abbott Diabetes Care
Director Global Market Access
Abbott Vascular
Healthcare Data Analyst EMEA
Agenas (Agency for Regional Health Services), Italy
Chief of Innovation, Research and Development Department
Alcon Pharma GmbH
Pricing manager
Alcon Pharma GmbH
Head of Key Account & Commercial Excellence
Alcon Pharmaceutical, Ltd.
Market Access Manager Czech & Slovak Republic
Ascensia Diabetes Care
Global Head Market Access & Policy, Executive Board Member of EDMA
BaseCase
Account Executive
BaseCase
Account Executive
Baxter
Senior Manager Market Access EMEA
BC consulting & Solutions
CEO and Principal
BD
HEOR Manager WEU
BD
Associate Director HEOR Europe
Biotronik SE & Co KG
Health Economics & Market Access Manager
Boston Healthcare
Vice President
Boston Healthcare
Director
Boston Scientific
Director Market Access Urology & Pelvic Health, Health Economics & Market Access Europe
Boston Scientific
Medical Affairs Manager EP, Europe
BRAHMS GmbH
Manager Global Health Economics & Pricing
BSN medical GmbH
Manager Regulatory Intelligence
BSN medical GmbH
SVP Scientific & Regulatory Affairs
CADTH
Vice-President of Medical Devices and Clinical Interventions
Clearview Healthcare Partners
Managing Director
Clearview Healthcare Partners
Associate Principal
Cook Medical
Reimbursement manager
Costello Medical Consulting
Head of Medical Devices
CytoSorbents
Senior Manager Reimbursement & Health Economics
Edwards Lifesciences
Vice President Market Access
Flen Health
Head of Regulatory Affairs
Fresenius Medical Care
Health Economics & Market Access Expert
Genomic Health Int'l Sarl
VP Market Access
Getinge - Maquet Cardiopulmonary
Clinical Affairs - Risk Manager
HAS-Sante
Member of the Board, President of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS)
HeartFlow
Director Health Economics
Hull Associates
Principal & Founder
Hull Associates
Senior Vice President, Europe
Hull Associates
Partner
Humanitas Research Hospital
Head of Clinical Engineering Service
Intuitive Surgical
Market Access Director - Hospital
Intuitive Surgical
Market Access Director - UK, Ireland, Nordics & Pan-European Policy
Intuitive Surgical
Market access manager
Invibio (a Victrex Europa company)
Commercial Manager EMEA
Johnson & Johnson
Market Access Manager
Johnson & Johnson Medical
Director Health Economics & Market Access DACH
Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA)
Director
MED-EL Elektromedizinische Geräte GmbH
Tender Manager
MedTech Europe
Director Market Access and Economic Policies
MedTech Europe
Manager Market Access & Economic Policies
Medtronic
Legal Council
Medtronic
Vice-President, Global Pricing Strategy & Revenue Management
Medtronic
Global Director Scientific Communications, Medical Affairs
Medtronic
Reimbursement and Health Economics Manager
Medtronic
Reimbursement and Health Economics Analyst
Merit Medical
Director Medical Affairs EMEA
ModelN
Sales Director, Europe
MTRC
CEO
MTRC
CEO
National Institute for Health and Care Excellence
Technical Analyst, NICE Scientific Advice Program
Neurescue
Director of Business Development
Neurescue
CEO
Nottingham University Hospitals NHS Trust
Medical Devices - Clinical Lead, Medical Physics & Clinical Engineering
Occlutech GmbH
Vice President Sales DACH / Nordics
Olympus
Health Economics Manager
Otto Bock
Corporate Vice President Clinical Research and Services
Otto Bock
Market access manager
Otto Bock France
Market access manager
Philips
Global Pricing Manager, PCMS Pricing Team
Philips Healthcare
Senior Pricing Manager Patient Care and Monitoring Solutions
POC Medical Systems
Vice President, Global Business Development
RAND Health
Senior Scientist
RIZIV-INAMI
Medical Adviser
RIZIV-INAMI
Scientific Evaluator
Roche
Market Access Manager
Scottish Health Technologies Group
Vice-Chair
Sirtex Medical Europe GmbH
Manager Market Access, Reimbursement & Health Economics DACH
SRH Hochschule Berlin (SRH University Berlin)
Professor for Healthcare Management
STAGO
Scientific Marketing Manager
Straub Medical
Principal Senior Market Access Consultant
Swedish Medtech (The association for medical technology)
Chief executive
Synergus
CEO
Synergus
Market Access Thought Leader
Terumo BCT
Global Director Government Affairs and Public Policy
Terumo BCT
Market Access Director EMEA
Terumo BTC
Market Access & Health Ecoomics Manager EMEA
ValueConnected
Managing Director
ValueConnected
Director of European Operations
W. L. Gore & Associates
Health Economics, Value Strategist, Market Access
ZOLL CMS GmbH
Reimbursement Manager
ZOLL CMS GmbH
VP International Sales

Related Videos

Presentation

How value-based approach is transforming the MedTech industry

Related topics: MedTech, Market Access & HEOR
Availability: FREE
  • Integrating market access, medical affairs and deep clinical understanding
  • Building a strategy with KOL engagement and collaboration with scientific societies - a case study explaining the process and decision-making algorithms
  • Clinical guidelines, the reimbursement system and medical standards and protocols as a key focus of the strategy
Speaker

Julya Zuenkova

Business Development Director
Xstrahl Group

Presentation

From value-based healthcare to network value

Related topics: MedTech, Market Access & HEOR
Availability: FREE

COVID-19 significantly impacted how providers reach out to patients. Besides, there has been a series of changes in the reimbursement and funding of medical technologies and procedures. These aspects created opportunities to address new market needs and leverage data and learning to deliver more value to a growing network of payers, providers, and patients. Welcome to the new era of Network Value.

Speaker

Ernesto M. Nogueira

CEO and Founder
ValueConnected

Pricing & Registration

3 Day Delegate Pass
period. prices until 28.03.2024!
Prices shown per delegate
1 Delegate
2 Delegates
3 Delegates
4+ Delegates
Corporate (Pharma / MedTech / BioTech)
1 Delegate
2,092 EUR
After 25% discount
2 Delegates
1,813 EUR
After 35% discount
3 Delegates
1,534 EUR
After 45% discount
4+ Delegates
1,395 EUR
After 50% discount
Solution Provider/Consultant
1 Delegate
2,790 EUR
2 Delegates
2,511 EUR
After 10% discount
3 Delegates
2,371 EUR
After 15% discount
4+ Delegates
2,232 EUR
After 20% discount
Government, Academic & Non-Profit
1 Delegate
499 EUR
2 Delegates
499 EUR
3 Delegates
499 EUR
4+ Delegates
499 EUR
Academic
1 Delegate
1,150 EUR
2 Delegates
1,150 EUR
3 Delegates
1,150 EUR
4+ Delegates
1,150 EUR
2 Day Delegate Pass
period. prices until 28.03.2024!
Prices shown per delegate
1 Delegate
2 Delegates
3 Delegates
4+ Delegates
Corporate (Pharma / MedTech / BioTech)
1 Delegate
1,717 EUR
After 25% discount
2 Delegates
1,488 EUR
After 35% discount
3 Delegates
1,259 EUR
After 45% discount
4+ Delegates
1,145 EUR
After 50% discount
Solution Provider/Consultant
1 Delegate
2,290 EUR
2 Delegates
2,061 EUR
After 10% discount
3 Delegates
1,946 EUR
After 15% discount
4+ Delegates
1,832 EUR
After 20% discount
Academic
1 Delegate
950 EUR
2 Delegates
950 EUR
3 Delegates
950 EUR
4+ Delegates
950 EUR
Government, Academic & Non-Profit
1 Delegate
499 EUR
2 Delegates
499 EUR
3 Delegates
499 EUR
4+ Delegates
499 EUR